2型糖尿病患者血浆chemerin水平与其冠脉病变程度的相关性分析

目的:探讨2型糖尿病患者血浆趋化素(chemerin)水平与冠脉病变程度的关系。方法:选取2011年1月~2012年2月我院收治的2型糖尿病(T2DM)患者92例,均行冠状动脉造影检查。按冠状动脉造影结果分为单纯2型糖尿病无冠状动脉病变组26例(DM0);合并单支冠状动脉病变组32例(DM1);合并双支以上病变组34例(DM2)。另选取正常健康行冠脉造影检查者25例作为正常对照组(NC)。采用酶联免疫吸附法检测各组入选者血浆chemerin水平,并分析其与冠脉病变程度的相关性。结果:T2DM及T2DM合并冠状动脉病变患者血浆chemerin水平与NC组对比均明显升高,并且与冠状动脉病变严重程度呈正相关(P0.05)。各组血浆Chemerin水平与BMI、HOMA-IR、TC、和APOB各指标间呈显著正相关(r分别为0.781、0.723、0.415、0.694,P均0.01)。结论:2型糖尿病患者冠状动脉病变的发生发展可能与血浆chemerin升高有关。

Research on the Correlation of Plasma Chemerin Level with the Severity of Coronary Artery Lesions in type 2 Diabetes Mellitus

Objective： To investigate the relationship between plasma chemerin level changes and coronary artery lesions in patients with type 2 diabetes. Methods： 82 patients with Type 2 diabetes mellitus （T2DM） were enrolled for the study and underwent coronary angiography. The patients were further grouped according to the results of coronary angiography into 3 groups. 26 patients with simple Type 2 Diabetes without coronary artery lesions were grouped DM0; 32 cases with only a single coronary artery disease were grouped DM1; 34 cases with multiple coronary artery disease （2 or more vessels involved） were grouped DM2. 25 normal healthy patients who underwent coronary angiography were selected as normal control group （NC）. ELISA method was used measure plasma chemerin levels. The plasma chemerin levels were compared with the body mass index （BMI）, indicators of insulin resistance index （HOMA-IR）, total cholesterol （CHOL）, apolipoprotein B （APOB）was done. Results： Compared to the normal control group, plasma chemerin levels in the T2DM and T2DM subgroup of multiple coronary artery disease patients was significantly increased and it positively correlated with the degree of coronary artery lesion （P〈0.05）. The plasma chemerin levels also positively correlated with apolipoprotein B, HOMA-IR, CHOL and BMI （P〈0.01）. Conclusion： The development of coronary artery lesions in patients with Type 2 Diabetes may be associated with elevated levels of plasma chemerin.